24-Nor Ursodeoxycholic Acid (CAS 99697-24-2)
QUICK LINKS
24-Nor Ursodeoxycholic Acid is a modified bile acid that has become the subject of various research studies focusing on hepatic physiology and the metabolism of cholesterol. In the realm of biochemistry, it is studied for its role in modulating bile acid pools and their enterohepatic circulation, which is essential for understanding lipid digestion and absorption. Studies involving this compound contribute to the knowledge of bile acid synthesis pathways and their regulatory mechanisms. Additionally, 24-Nor Ursodeoxycholic Acid is used in the investigation of the physical-chemical properties of bile, such as micelle formation and solubilization of lipids. Environmental scientists also study this compound to trace the transformation and fate of steroidal compounds in aquatic ecosystems.
24-Nor Ursodeoxycholic Acid (CAS 99697-24-2) References
- Pharmacotherapy of cholestatic liver diseases. | Paumgartner, G. 2010. J Dig Dis. 11: 119-25. PMID: 20579215
- Nor-ursodeoxycholic acid reverses hepatocyte-specific nemo-dependent steatohepatitis. | Beraza, N., et al. 2011. Gut. 60: 387-96. PMID: 21115542
- Loss of CFTR affects biliary epithelium innate immunity and causes TLR4-NF-κB-mediated inflammatory response in mice. | Fiorotto, R., et al. 2011. Gastroenterology. 141: 1498-508, 1508.e1-5. PMID: 21712022
- Differential effects of norUDCA and UDCA in obstructive cholestasis in mice. | Fickert, P., et al. 2013. J Hepatol. 58: 1201-8. PMID: 23369794
- 24-nor-ursodeoxycholic acid ameliorates inflammatory response and liver fibrosis in a murine model of hepatic schistosomiasis. | Sombetzki, M., et al. 2015. J Hepatol. 62: 871-8. PMID: 25463533
- Vector-mediated microRNA-21 silencing ameliorates granulomatous liver fibrosis in Schistosoma japonicum infection. | Sombetzki, M., et al. 2015. Hepatology. 61: 1787-9. PMID: 25684616
- Potential of nor-Ursodeoxycholic Acid in Cholestatic and Metabolic Disorders. | Trauner, M., et al. 2015. Dig Dis. 33: 433-9. PMID: 26045280
- Therapy of Primary Sclerosing Cholangitis--Today and Tomorrow. | Halilbasic, E., et al. 2015. Dig Dis. 33 Suppl 2: 149-63. PMID: 26641242
- Influence of 24-Nor-Ursodeoxycholic Acid on Hepatic Disposition of [(18)F]Ciprofloxacin, a Positron Emission Tomography Study in Mice. | Wanek, T., et al. 2016. J Pharm Sci. 105: 106-12. PMID: 26852845
- Therapeutic Mechanisms of Bile Acids and Nor-Ursodeoxycholic Acid in Non-Alcoholic Fatty Liver Disease. | Steinacher, D., et al. 2017. Dig Dis. 35: 282-287. PMID: 28249257
- Semisynthetic bile acids: a new therapeutic option for metabolic syndrome. | Lazarević, S., et al. 2019. Pharmacol Res. 146: 104333. PMID: 31254667
- Evidence for functional selectivity in TUDC- and norUDCA-induced signal transduction via α5β1 integrin towards choleresis. | Bonus, M., et al. 2020. Sci Rep. 10: 5795. PMID: 32242141
- Monomeric bile acids modulate the ATPase activity of detergent-solubilized ABCB4/MDR3. | Kroll, T., et al. 2021. J Lipid Res. 62: 100087. PMID: 34022183
- Beneficial effects of UDCA and norUDCA in a rodent model of steatosis are linked to modulation of GPBAR1/FXR signaling. | Marchianò, S., et al. 2022. Biochim Biophys Acta Mol Cell Biol Lipids. 1867: 159218. PMID: 35985473
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
24-Nor Ursodeoxycholic Acid, 1 mg | sc-478796 | 1 mg | $401.00 |